{"id":"W4281631797","doi":"10.1200/jco.2022.40.16_suppl.8006","title":"Initial safety results for MagnetisMM-3: A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Pfizer","keywords":"Medicine; Cytokine release syndrome; Internal medicine; Adverse effect; Gastroenterology; Regimen; Toxicity; Cohort; Antibody; Oncology; Immunology; Cancer; Chimeric antigen receptor; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007216126,0.000227533,0.001878583,0.0005671217,0.0001149216,0.00001267671,0.0003569738,0.0003821735,0.0007713941],"category_scores_gemma":[0.003991077,0.0001806553,0.0005735487,0.0004874403,0.0002929577,0.0001933344,0.0001246999,0.002024036,0.000004533766],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004716619,"about_ca_system_score_gemma":0.002443019,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005205762,"about_ca_topic_score_gemma":0.00009676026,"domain_scores_codex":[0.99218,0.001465057,0.004289779,0.0004113121,0.001218506,0.0004353093],"domain_scores_gemma":[0.9907256,0.00475945,0.002936235,0.0004096395,0.0008382224,0.0003307968],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8406119,0.01856185,0.006026592,0.00005863967,0.000188504,0.0004552596,0.0003285491,0.00004203807,0.005457853,0.000008345625,0.003419803,0.1248407],"study_design_scores_gemma":[0.5726732,0.1865598,0.04971308,0.00007877435,0.0001384488,0.0000697849,0.0002897711,0.0004008899,0.0004845219,0.00003696497,0.1893912,0.0001635135],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9919752,0.000148508,0.0001567432,0.00157101,0.001702997,0.00216889,0.0002245555,0.0000102707,0.002041817],"genre_scores_gemma":[0.9950328,0.000543675,0.002024836,0.0003185252,0.001173978,0.00003380976,0.000236913,0.00004793047,0.0005874793],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2679387,"threshold_uncertainty_score":0.8793541,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09750823413975031,"score_gpt":0.4644746690344346,"score_spread":0.3669664348946843,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}